Edwards Lifesciences Provides Earnings Guidance for the First Quarter and Full Year of 2022
For the full year, the company expects sales grow at a low double-digit rate to $5.5 billion to $6.0 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
87.73 USD | -1.98% |
|
-6.15% | +15.06% |
07-16 | Truist Raises Price Target on Edwards Lifesciences to $110 From $105, Maintains Buy Rating | MT |
07-15 | Sector Update: Health Care Stocks Edge Lower Late Afternoon | MT |
1st Jan change | Capi. | |
---|---|---|
+15.06% | 52.87B | |
+4.64% | 212B | |
+8.99% | 187B | |
+29.83% | 155B | |
+35.17% | 115B | |
+2.36% | 65.5B | |
-6.47% | 45.25B | |
-2.14% | 39.7B | |
+6.88% | 37.72B | |
+20.22% | 30.38B |